Agonistic antibacterial potential of Loigolactobacillus coryniformis BCH-4 metabolites against selected human pathogenic bacteria: An in vitro and in silico approach
Lactic acid bacteria are known to produce numerous antibacterial metabolites that are active against various pathogenic microbes. In this study, bioactive metabolites from the cell free supernatant of Loigolactobacillus coryniformis BCH-4 were obtained by liquid-liquid extraction, using ethyl acetat...
Gespeichert in:
| Veröffentlicht in: | PloS one 2023-08, Vol.18 (8), p.e0289723-e0289723 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0289723 |
|---|---|
| container_issue | 8 |
| container_start_page | e0289723 |
| container_title | PloS one |
| container_volume | 18 |
| creator | Tariq, Anam Salman, Mahwish Mustafa, Ghulam Tawab, Abdul Naheed, Shazia Naz, Hafsa Shahid, Misbah Ali, Hazrat |
| description | Lactic acid bacteria are known to produce numerous antibacterial metabolites that are active against various pathogenic microbes. In this study, bioactive metabolites from the cell free supernatant of Loigolactobacillus coryniformis BCH-4 were obtained by liquid-liquid extraction, using ethyl acetate, followed by fractionation, using silica gel column chromatography. The collected F23 fraction effectively inhibited the growth of pathogenic bacteria (Escherichia coli, Bacillus cereus, and Staphylococcus aureus) by observing the minimum inhibitory concentration (MIC) and minimum bactericidal concentrations (MBC). The evaluated values of MIC were 15.6 ± 0.34, 3.9 ± 0.59, and 31.2 ± 0.67 μg/mL and MBC were 15.6 ± 0.98, 7.8 ± 0.45, and 62.5 ± 0.23 μg/mL respectively, against the above-mentioned pathogenic bacteria. The concentration of F23 fraction was varying from 1000 to 1.9 μg/mL. Furthermore, the fraction also exhibited sustainable biofilm inhibition. Using the Electrospray Ionization Mass Spectrometry (ESI-MS/MS), the metabolites present in the bioactive fraction (F23), were identified as phthalic acid, myristic acid, mangiferin, 16-hydroxylpalmatic acid, apigenin, and oleandomycin. By using in silico approach, docking analysis showed good interaction of identified metabolites and receptor proteins of pathogenic bacteria. The present study suggested Loigolactobacillus coryniformis BCH-4, as a promising source of natural bioactive metabolites which may receive great benefit as potential sources of drugs in the pharmacological sector. |
| doi_str_mv | 10.1371/journal.pone.0289723 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2848829568</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A760321882</galeid><sourcerecordid>A760321882</sourcerecordid><originalsourceid>FETCH-LOGICAL-c627t-c43871e6476eaf588d83ba7f60b2ac5920bd25870c89488465881a15ea82a2043</originalsourceid><addsrcrecordid>eNqNk12L3CAUhkNp6W63_QelFQqlvZip0cSY3pTp0o-FhYV-3cqJMYmLo1k1S_cH9X_WsJllpuxF8UKPPue88urJsuc5Xue0yt9duslbMOvRWbXGhNcVoQ-y47ymZMUIpg_31kfZkxAuMS4pZ-xxdkSrkuWsqo-zP5veWR2ilghs1A3IqLwGg0YXVdpIK9ehc6d7Z9KZS4A2ZgpIOn9jdef8Vgf08fTrqkBbFaFxRkcVEPSgbYgoKKNSyRYN0xYsGiEOrlc2ye2k3qONRdqiax29S5do5yBoo2WKxtE7kMPT7FEHJqhny3yS_fz86UcSPb_4cna6OV9JRqq4kgXlVa5YUTEFXcl5y2kDVcdwQ0CWNcFNS0peYcnrgvOCJSSHvFTACRBc0JPs5W3d0bggFoeDIDzRpC4ZT8SHhZiarWpl8siDEaPXW_A3woEWhydWD6J31yLHRV6UbNZ4s1Tw7mpSIYrkoFTGgFVumsVKTHHNizKhr_5B77_SQvVglNC2c0lYzkXFpmKYkjyRiVrfQ6XRqm2y2qpOp_2DhLcHCYmJ6nfsYQpBnH3_9v_sxa9D9vUeOygwcQjOTFE7Gw7B4haU3oXgVXfnco7F3AI7N8TcAmJpgZT2Yv-F7pJ2f57-BVgEA9E</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2848829568</pqid></control><display><type>article</type><title>Agonistic antibacterial potential of Loigolactobacillus coryniformis BCH-4 metabolites against selected human pathogenic bacteria: An in vitro and in silico approach</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Tariq, Anam ; Salman, Mahwish ; Mustafa, Ghulam ; Tawab, Abdul ; Naheed, Shazia ; Naz, Hafsa ; Shahid, Misbah ; Ali, Hazrat</creator><contributor>Nevárez-Moorillón, Guadalupe Virginia</contributor><creatorcontrib>Tariq, Anam ; Salman, Mahwish ; Mustafa, Ghulam ; Tawab, Abdul ; Naheed, Shazia ; Naz, Hafsa ; Shahid, Misbah ; Ali, Hazrat ; Nevárez-Moorillón, Guadalupe Virginia</creatorcontrib><description>Lactic acid bacteria are known to produce numerous antibacterial metabolites that are active against various pathogenic microbes. In this study, bioactive metabolites from the cell free supernatant of Loigolactobacillus coryniformis BCH-4 were obtained by liquid-liquid extraction, using ethyl acetate, followed by fractionation, using silica gel column chromatography. The collected F23 fraction effectively inhibited the growth of pathogenic bacteria (Escherichia coli, Bacillus cereus, and Staphylococcus aureus) by observing the minimum inhibitory concentration (MIC) and minimum bactericidal concentrations (MBC). The evaluated values of MIC were 15.6 ± 0.34, 3.9 ± 0.59, and 31.2 ± 0.67 μg/mL and MBC were 15.6 ± 0.98, 7.8 ± 0.45, and 62.5 ± 0.23 μg/mL respectively, against the above-mentioned pathogenic bacteria. The concentration of F23 fraction was varying from 1000 to 1.9 μg/mL. Furthermore, the fraction also exhibited sustainable biofilm inhibition. Using the Electrospray Ionization Mass Spectrometry (ESI-MS/MS), the metabolites present in the bioactive fraction (F23), were identified as phthalic acid, myristic acid, mangiferin, 16-hydroxylpalmatic acid, apigenin, and oleandomycin. By using in silico approach, docking analysis showed good interaction of identified metabolites and receptor proteins of pathogenic bacteria. The present study suggested Loigolactobacillus coryniformis BCH-4, as a promising source of natural bioactive metabolites which may receive great benefit as potential sources of drugs in the pharmacological sector.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0289723</identifier><identifier>PMID: 37561679</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acetic acid ; Analysis ; Antibacterial agents ; Antibiotics ; Antiinfectives and antibacterials ; Bacteria ; Bioactive compounds ; Biofilms ; Biological activity ; Biology and Life Sciences ; Care and treatment ; Chromatography ; Chronic fatigue syndrome ; Coliforms ; Column chromatography ; Complications and side effects ; Diagnosis ; Drug resistance ; E coli ; Esters ; Ethyl acetate ; Fatty acids ; Fractionation ; Ionization ; Ions ; Lactic acid ; Lactic acid bacteria ; Liquid-liquid extraction ; Mass spectrometry ; Mass spectroscopy ; Medicine and Health Sciences ; Metabolites ; Methicillin ; Minimum inhibitory concentration ; Natural products ; Oleandomycin ; Patient outcomes ; Pharmaceutical industry ; Phthalic acid ; Proteins ; Research and Analysis Methods ; Silica ; Silica gel ; Solvents ; Staphylococcus aureus ; Staphylococcus aureus infections</subject><ispartof>PloS one, 2023-08, Vol.18 (8), p.e0289723-e0289723</ispartof><rights>Copyright: © 2023 Tariq et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2023 Public Library of Science</rights><rights>2023 Tariq et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 Tariq et al 2023 Tariq et al</rights><rights>2023 Tariq et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c627t-c43871e6476eaf588d83ba7f60b2ac5920bd25870c89488465881a15ea82a2043</citedby><cites>FETCH-LOGICAL-c627t-c43871e6476eaf588d83ba7f60b2ac5920bd25870c89488465881a15ea82a2043</cites><orcidid>0000-0002-8266-2360 ; 0000-0001-6255-3696 ; 0000-0001-6510-6496 ; 0000-0003-3063-6520</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414564/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414564/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2926,23865,27923,27924,53790,53792,79371,79372</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37561679$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Nevárez-Moorillón, Guadalupe Virginia</contributor><creatorcontrib>Tariq, Anam</creatorcontrib><creatorcontrib>Salman, Mahwish</creatorcontrib><creatorcontrib>Mustafa, Ghulam</creatorcontrib><creatorcontrib>Tawab, Abdul</creatorcontrib><creatorcontrib>Naheed, Shazia</creatorcontrib><creatorcontrib>Naz, Hafsa</creatorcontrib><creatorcontrib>Shahid, Misbah</creatorcontrib><creatorcontrib>Ali, Hazrat</creatorcontrib><title>Agonistic antibacterial potential of Loigolactobacillus coryniformis BCH-4 metabolites against selected human pathogenic bacteria: An in vitro and in silico approach</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Lactic acid bacteria are known to produce numerous antibacterial metabolites that are active against various pathogenic microbes. In this study, bioactive metabolites from the cell free supernatant of Loigolactobacillus coryniformis BCH-4 were obtained by liquid-liquid extraction, using ethyl acetate, followed by fractionation, using silica gel column chromatography. The collected F23 fraction effectively inhibited the growth of pathogenic bacteria (Escherichia coli, Bacillus cereus, and Staphylococcus aureus) by observing the minimum inhibitory concentration (MIC) and minimum bactericidal concentrations (MBC). The evaluated values of MIC were 15.6 ± 0.34, 3.9 ± 0.59, and 31.2 ± 0.67 μg/mL and MBC were 15.6 ± 0.98, 7.8 ± 0.45, and 62.5 ± 0.23 μg/mL respectively, against the above-mentioned pathogenic bacteria. The concentration of F23 fraction was varying from 1000 to 1.9 μg/mL. Furthermore, the fraction also exhibited sustainable biofilm inhibition. Using the Electrospray Ionization Mass Spectrometry (ESI-MS/MS), the metabolites present in the bioactive fraction (F23), were identified as phthalic acid, myristic acid, mangiferin, 16-hydroxylpalmatic acid, apigenin, and oleandomycin. By using in silico approach, docking analysis showed good interaction of identified metabolites and receptor proteins of pathogenic bacteria. The present study suggested Loigolactobacillus coryniformis BCH-4, as a promising source of natural bioactive metabolites which may receive great benefit as potential sources of drugs in the pharmacological sector.</description><subject>Acetic acid</subject><subject>Analysis</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antiinfectives and antibacterials</subject><subject>Bacteria</subject><subject>Bioactive compounds</subject><subject>Biofilms</subject><subject>Biological activity</subject><subject>Biology and Life Sciences</subject><subject>Care and treatment</subject><subject>Chromatography</subject><subject>Chronic fatigue syndrome</subject><subject>Coliforms</subject><subject>Column chromatography</subject><subject>Complications and side effects</subject><subject>Diagnosis</subject><subject>Drug resistance</subject><subject>E coli</subject><subject>Esters</subject><subject>Ethyl acetate</subject><subject>Fatty acids</subject><subject>Fractionation</subject><subject>Ionization</subject><subject>Ions</subject><subject>Lactic acid</subject><subject>Lactic acid bacteria</subject><subject>Liquid-liquid extraction</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>Medicine and Health Sciences</subject><subject>Metabolites</subject><subject>Methicillin</subject><subject>Minimum inhibitory concentration</subject><subject>Natural products</subject><subject>Oleandomycin</subject><subject>Patient outcomes</subject><subject>Pharmaceutical industry</subject><subject>Phthalic acid</subject><subject>Proteins</subject><subject>Research and Analysis Methods</subject><subject>Silica</subject><subject>Silica gel</subject><subject>Solvents</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus infections</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNk12L3CAUhkNp6W63_QelFQqlvZip0cSY3pTp0o-FhYV-3cqJMYmLo1k1S_cH9X_WsJllpuxF8UKPPue88urJsuc5Xue0yt9duslbMOvRWbXGhNcVoQ-y47ymZMUIpg_31kfZkxAuMS4pZ-xxdkSrkuWsqo-zP5veWR2ilghs1A3IqLwGg0YXVdpIK9ehc6d7Z9KZS4A2ZgpIOn9jdef8Vgf08fTrqkBbFaFxRkcVEPSgbYgoKKNSyRYN0xYsGiEOrlc2ye2k3qONRdqiax29S5do5yBoo2WKxtE7kMPT7FEHJqhny3yS_fz86UcSPb_4cna6OV9JRqq4kgXlVa5YUTEFXcl5y2kDVcdwQ0CWNcFNS0peYcnrgvOCJSSHvFTACRBc0JPs5W3d0bggFoeDIDzRpC4ZT8SHhZiarWpl8siDEaPXW_A3woEWhydWD6J31yLHRV6UbNZ4s1Tw7mpSIYrkoFTGgFVumsVKTHHNizKhr_5B77_SQvVglNC2c0lYzkXFpmKYkjyRiVrfQ6XRqm2y2qpOp_2DhLcHCYmJ6nfsYQpBnH3_9v_sxa9D9vUeOygwcQjOTFE7Gw7B4haU3oXgVXfnco7F3AI7N8TcAmJpgZT2Yv-F7pJ2f57-BVgEA9E</recordid><startdate>20230810</startdate><enddate>20230810</enddate><creator>Tariq, Anam</creator><creator>Salman, Mahwish</creator><creator>Mustafa, Ghulam</creator><creator>Tawab, Abdul</creator><creator>Naheed, Shazia</creator><creator>Naz, Hafsa</creator><creator>Shahid, Misbah</creator><creator>Ali, Hazrat</creator><general>Public Library of Science</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8266-2360</orcidid><orcidid>https://orcid.org/0000-0001-6255-3696</orcidid><orcidid>https://orcid.org/0000-0001-6510-6496</orcidid><orcidid>https://orcid.org/0000-0003-3063-6520</orcidid></search><sort><creationdate>20230810</creationdate><title>Agonistic antibacterial potential of Loigolactobacillus coryniformis BCH-4 metabolites against selected human pathogenic bacteria: An in vitro and in silico approach</title><author>Tariq, Anam ; Salman, Mahwish ; Mustafa, Ghulam ; Tawab, Abdul ; Naheed, Shazia ; Naz, Hafsa ; Shahid, Misbah ; Ali, Hazrat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c627t-c43871e6476eaf588d83ba7f60b2ac5920bd25870c89488465881a15ea82a2043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acetic acid</topic><topic>Analysis</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antiinfectives and antibacterials</topic><topic>Bacteria</topic><topic>Bioactive compounds</topic><topic>Biofilms</topic><topic>Biological activity</topic><topic>Biology and Life Sciences</topic><topic>Care and treatment</topic><topic>Chromatography</topic><topic>Chronic fatigue syndrome</topic><topic>Coliforms</topic><topic>Column chromatography</topic><topic>Complications and side effects</topic><topic>Diagnosis</topic><topic>Drug resistance</topic><topic>E coli</topic><topic>Esters</topic><topic>Ethyl acetate</topic><topic>Fatty acids</topic><topic>Fractionation</topic><topic>Ionization</topic><topic>Ions</topic><topic>Lactic acid</topic><topic>Lactic acid bacteria</topic><topic>Liquid-liquid extraction</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>Medicine and Health Sciences</topic><topic>Metabolites</topic><topic>Methicillin</topic><topic>Minimum inhibitory concentration</topic><topic>Natural products</topic><topic>Oleandomycin</topic><topic>Patient outcomes</topic><topic>Pharmaceutical industry</topic><topic>Phthalic acid</topic><topic>Proteins</topic><topic>Research and Analysis Methods</topic><topic>Silica</topic><topic>Silica gel</topic><topic>Solvents</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tariq, Anam</creatorcontrib><creatorcontrib>Salman, Mahwish</creatorcontrib><creatorcontrib>Mustafa, Ghulam</creatorcontrib><creatorcontrib>Tawab, Abdul</creatorcontrib><creatorcontrib>Naheed, Shazia</creatorcontrib><creatorcontrib>Naz, Hafsa</creatorcontrib><creatorcontrib>Shahid, Misbah</creatorcontrib><creatorcontrib>Ali, Hazrat</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tariq, Anam</au><au>Salman, Mahwish</au><au>Mustafa, Ghulam</au><au>Tawab, Abdul</au><au>Naheed, Shazia</au><au>Naz, Hafsa</au><au>Shahid, Misbah</au><au>Ali, Hazrat</au><au>Nevárez-Moorillón, Guadalupe Virginia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Agonistic antibacterial potential of Loigolactobacillus coryniformis BCH-4 metabolites against selected human pathogenic bacteria: An in vitro and in silico approach</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2023-08-10</date><risdate>2023</risdate><volume>18</volume><issue>8</issue><spage>e0289723</spage><epage>e0289723</epage><pages>e0289723-e0289723</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Lactic acid bacteria are known to produce numerous antibacterial metabolites that are active against various pathogenic microbes. In this study, bioactive metabolites from the cell free supernatant of Loigolactobacillus coryniformis BCH-4 were obtained by liquid-liquid extraction, using ethyl acetate, followed by fractionation, using silica gel column chromatography. The collected F23 fraction effectively inhibited the growth of pathogenic bacteria (Escherichia coli, Bacillus cereus, and Staphylococcus aureus) by observing the minimum inhibitory concentration (MIC) and minimum bactericidal concentrations (MBC). The evaluated values of MIC were 15.6 ± 0.34, 3.9 ± 0.59, and 31.2 ± 0.67 μg/mL and MBC were 15.6 ± 0.98, 7.8 ± 0.45, and 62.5 ± 0.23 μg/mL respectively, against the above-mentioned pathogenic bacteria. The concentration of F23 fraction was varying from 1000 to 1.9 μg/mL. Furthermore, the fraction also exhibited sustainable biofilm inhibition. Using the Electrospray Ionization Mass Spectrometry (ESI-MS/MS), the metabolites present in the bioactive fraction (F23), were identified as phthalic acid, myristic acid, mangiferin, 16-hydroxylpalmatic acid, apigenin, and oleandomycin. By using in silico approach, docking analysis showed good interaction of identified metabolites and receptor proteins of pathogenic bacteria. The present study suggested Loigolactobacillus coryniformis BCH-4, as a promising source of natural bioactive metabolites which may receive great benefit as potential sources of drugs in the pharmacological sector.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>37561679</pmid><doi>10.1371/journal.pone.0289723</doi><tpages>e0289723</tpages><orcidid>https://orcid.org/0000-0002-8266-2360</orcidid><orcidid>https://orcid.org/0000-0001-6255-3696</orcidid><orcidid>https://orcid.org/0000-0001-6510-6496</orcidid><orcidid>https://orcid.org/0000-0003-3063-6520</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2023-08, Vol.18 (8), p.e0289723-e0289723 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2848829568 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Acetic acid Analysis Antibacterial agents Antibiotics Antiinfectives and antibacterials Bacteria Bioactive compounds Biofilms Biological activity Biology and Life Sciences Care and treatment Chromatography Chronic fatigue syndrome Coliforms Column chromatography Complications and side effects Diagnosis Drug resistance E coli Esters Ethyl acetate Fatty acids Fractionation Ionization Ions Lactic acid Lactic acid bacteria Liquid-liquid extraction Mass spectrometry Mass spectroscopy Medicine and Health Sciences Metabolites Methicillin Minimum inhibitory concentration Natural products Oleandomycin Patient outcomes Pharmaceutical industry Phthalic acid Proteins Research and Analysis Methods Silica Silica gel Solvents Staphylococcus aureus Staphylococcus aureus infections |
| title | Agonistic antibacterial potential of Loigolactobacillus coryniformis BCH-4 metabolites against selected human pathogenic bacteria: An in vitro and in silico approach |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T19%3A20%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Agonistic%20antibacterial%20potential%20of%20Loigolactobacillus%20coryniformis%20BCH-4%20metabolites%20against%20selected%20human%20pathogenic%20bacteria:%20An%20in%20vitro%20and%20in%20silico%20approach&rft.jtitle=PloS%20one&rft.au=Tariq,%20Anam&rft.date=2023-08-10&rft.volume=18&rft.issue=8&rft.spage=e0289723&rft.epage=e0289723&rft.pages=e0289723-e0289723&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0289723&rft_dat=%3Cgale_plos_%3EA760321882%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2848829568&rft_id=info:pmid/37561679&rft_galeid=A760321882&rfr_iscdi=true |